Advertising Feature

BugBiome and UroPharma move to Norwich Research Park

Roz Bird, CEO, Anglia Innovation Partnership and Alicia Showering, CEO of BugBiome <i>(Image: Lee Blanchflower)</i>
Roz Bird, CEO, Anglia Innovation Partnership and Alicia Showering, CEO of BugBiome (Image: Lee Blanchflower)
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The Herald.

As Norwich Research Park ’s reputation continues to grow as a hotbed for start-up companies combining innovation, science and enterprise, two more companies are moving onto the campus.

BugBiome and UroPharma have both just agreed tenancies for laboratory and office accommodation.  

BugBiome – developing alternatives to chemical pesticides  

BugBiome is an agri-biotech start-up company that is moving to Norwich Research Park from its previous home at the National Institute for Agricultural Botany (NIAB) in Cambridge.

It is currently developing a new bioinsecticide product, an aphicide, which aims to provide protection for crops such as potatoes, sugar beet and oilseed rape against aphid infestations which can devastate harvests. The product has been developed from using crop-associated microbes found in plants. 

BugBiome is creating a product to protect crops such as potatoes, sugar beet and oilseed rape against aphid infestations (Image: BugBiome)

Due to changes in the regulations governing agriculture, farmers must reduce the amount of chemical-based insecticides used on their crops. That means the industry is actively looking for credible alternatives.

Currently, farmers have few options – but BugBiome is aiming to develop a range of products that will meet these requirements. The start-up will be testing the efficacy of its aphicide product in field trials next year.

READ MORE: BioP creates virus-free potatoes at Norwich Research Park

It has been able to make the move to Norwich Research Park and fund its trials and further research following recent investment from European Agfunds Rockstart and Biotope. Proceeds from its ongoing fundraising round will further support the development and commercialisation of its discovery platform, AvidX, as well as generating a pipeline of products targeting cabbage stem flea beetles, diamond back moth and more, broadening BugBiome’s reach across major crop pests. 

Alicia Showering and Chris Mosedale of BugBiome (Image: BugBiome)

There are a number of reasons that make moving to Norwich Research Park attractive to BugBiome.

First, to run and validate field trials for its new product. Second, to conduct further research using specialist laboratories. And third, to tap into the expertise of the plant and genome scientists at the John Innes Centre and Earlham Institute – all of whom are in close proximity on one site. It will also benefit from being part of the growing agri-food cluster and community activity at the Norwich Research Park campus. 

Alicia Showering, CEO of BugBiome (Image: BugBiome)

Dr Alicia Showering, CEO and co-founder of BugBiome, said: “Demonstrating field efficacy of our aphid product is a critical milestone for commercialisation and partnering. The environment at Norwich Research Park will enable us to accelerate not only this product, but also the broader portfolio of new bioinsecticide solutions farmers urgently need.

"The move to Norwich places us at the heart of the UK’s agri-biotech community. Our relocation and integration have gone well and we are delighted to enter the next phase of our development here.” 

UroPharma – making bladder treatments more effective  

Co-founded by business development director Howard Shapland and CEO Prof Scott Glickman, UroPharma is the latest business to move to Norwich Research Park. 

It is a pioneering MedTech company developing precision drug-device platforms for bladder health that is set to launch the world’s first licensed direct-to-bladder drainage and drug delivery system.

One of the key reasons UroPharma has relocated to the campus is to collaborate with the world-class microbiologists and translational scientists working at the four research institutes, university and university hospital. 

UroPharma aims to alleviate the suffering of those living with urinary tract infections, overactive bladder syndrome and bladder cancer (Image: UroPharma)

UroPharma’s mission is to alleviate the suffering of the many millions of people globally whose lives are blighted by problems such as recurrent urinary tract infections (UTIs), overactive bladder syndrome and bladder cancer.

According to a recent government report on the burden of UTIs , for the 2023-2024 financial year there were 189,756 hospital admissions for UTIs in England. This led to over 1.2 million NHS bed-days at a total cost of more than £604 million. 

By using UroPharma’s patented technology to deliver medication directly to the bladder, patients will receive the correct dose directly to the affected tissue.

READ MORE: Norwich Research Park incubation system helps start-ups grow

Not only should direct targeting be more effective at treating these conditions, but it will also avoid the damage done when patients take medicine for bladder conditions orally, which is currently the most frequent treatment method.

Oral treatments for urinary urgency have been known to result in dementia in some people. Meanwhile, the growth of antimicrobial resistance is being fuelled by oral treatments for UTIs. 

UroPharma expects to obtain regulatory approval for its urinary catheter in the next few months after which it aims to have it available for use in the NHS, followed by expansion into Europe and the wider global healthcare market.

The company’s premise that the right drugs are being given in the wrong way is already well supported by scientists at the University of East Anglia (UEA) and consultants at both the Norfolk and Norwich University Hospital (NNUH) and the Queen Elizabeth II Hospital in Kings Lynn .  

The NNUH’s forward-looking urology department has already established a strong working relationship with UroPharma. The move to Norwich Research Park will also enhance UroPharma’s long-established collaborations with Prof Sheng Qi at UEA and Prof Mark Webber at the Quadram Institute . 

Prof Scott Glickman, CEO of UroPharma (Image: UroPharma)

UroPharma hopes that the collaborations with both NNUH and the Community Trust leads to them being in the vanguard of health services to use its innovative technologies. 

Prof Glickman, who has been a medical consultant in the NHS and an award-winning healthcare technology inventor, said: “We are really excited to have relocated to Norwich Research Park because  it has such great links to a wealth of expert scientists, especially in microbiology and pharmacology, who are eager to help us achieve our aims.

"Our move to the Park campus will accelerate our progress. The enthusiasm and vitality here is just great. There’s definitely something really special going on here in Norfolk!” 

Roz Bird, CEO of Anglia Innovation Partnership (Image: Chris Ball Photography)

Roz Bird, CEO of Anglia Innovation Partnership, the campus management organisation for Norwich Research Park, said, “We have worked hard over the last three years to broadcast the message about the benefits of being based at Norwich Research Park as it’s an ideal home for companies operating in the agri-biotech, food biotech, industrial biotech and medtech industries.

"It’s great that BugBiome and UroPharma have made the decision to move here, recognising the breadth and depth of our research expertise, the state-of-the-art facilities, room to grow, a supportive community and a growing audience of investors.  

“We have a healthy pipeline of interest from companies from all over the world who are considering Norwich Research Park as a location for their business. These are all new connections that the campus management team at Anglia Innovation Partnership is managing.” 

For more information, visit norwichresearchpark.com

Get involved
with the news

Send your news & photos